Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04534842 · ClinicalTrials.gov registry record · Phase 2
Efficacy and Safety of SYNB1618 and SYNB1934 in Adult Patients With Phenylketonuria
A Phase 2 study, sponsored by Synlogic.
- Completed
- Registry status
- Phase 2
- Development phase
- 20
- Enrollment target
NCT04534842 is a Phase 2 study that has completed, run by Synlogic. The registered enrollment target is 20 participants.
The verdict
NCT04534842, a Phase 2 study, has completed, sponsored by Synlogic.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 20 participants
- Enrollment target
Study Summary
This Phase 2 study in patients with phenylketonuria (PKU) will be an open-label, dual-arm study of either a SYNB1618 or SYNB1934 dose-ramp regimen. All evaluations and assessments throughout this study may be conducted either at the clinical site or by a home healthcare professional at an alternative location (e.g., patient's home, hotel).
Interventions
- DRUG SYNB1934
- DRUG SYNB1618
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2020-08-25 |
| Est. Completion | 2022-10-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04534842
The ClinicalTrials.gov registry entry for NCT04534842 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Synlogic, which has 10 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which SYNB1934 is the first listed.
NCT04534842 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04534842 about?
NCT04534842 is a clinical study titled "Efficacy and Safety of SYNB1618 and SYNB1934 in Adult Patients With Phenylketonuria". This Phase 2 study in patients with phenylketonuria (PKU) will be an open-label, dual-arm study of either a SYNB1618 or SYNB1934 dose-ramp regimen. All evaluations and assessments throughout this study may be conducted either at the clinical site or by a home healthcare professional at an alternativ...
What is the current status of trial NCT04534842?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 20 participants. The study started on 2020-08-25. Estimated completion is 2022-10-07.
What interventions are being tested in trial NCT04534842?
The interventions under investigation include: SYNB1934 (DRUG), SYNB1618 (DRUG).
Who is sponsoring clinical trial NCT04534842?
This trial is sponsored by Synlogic, which has 10 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.